BACKGROUND Aggressive giant cell tumor of the distal fibula is so rare that no consensus on a surgical strategy has been reached.Thus,an appropriate treatment strategy is still important to discuss.CASE SUMMARY A 61-y...BACKGROUND Aggressive giant cell tumor of the distal fibula is so rare that no consensus on a surgical strategy has been reached.Thus,an appropriate treatment strategy is still important to discuss.CASE SUMMARY A 61-year-old man who had been experiencing progressive swelling of the left lateral malleolus accompanied by pain for half a year was presented at our hospital.He had never been treated prior to coming to our hospital.Preoperative imaging revealed a 10 cm×6 cm mass located in the body of the distal fibula.Pathological biopsies confirmed it was a giant cell tumor.Preoperative examination revealed he had dilated cardiomyopathy with class 3 cardiac function.The cardiologist and anesthesiologist determined that he could tolerate the operation,but the operation should be as short and minimally invasive as possible.With the patient’s consent,we performed a tibiotalar fusion and followed up with him for 2years,finding no recurrence and a satisfactory recovery.CONCLUSION Tibial talus fusion is an effective method for the treatment of distal fibula tumors.展开更多
Giant cell tumour of the distal radius is the 3rd most common site after proximal tibia and distal femur. It is locally aggressive and is associated with a high rate of recurrence. Although it is usually treated with ...Giant cell tumour of the distal radius is the 3rd most common site after proximal tibia and distal femur. It is locally aggressive and is associated with a high rate of recurrence. Although it is usually treated with various modalities of treatment, wide resection and reconstruction with proximal fibular autograft is most commonly accepted in recurrent cases. The following is a case report of such a case with surgical management.展开更多
Giant cell tumor is a benign primary bone tumor. The phalangeal localization is rare. It is distinguished from other locations by the local aggressiveness of the tumor and a high rate of recurrence. We report one case...Giant cell tumor is a benign primary bone tumor. The phalangeal localization is rare. It is distinguished from other locations by the local aggressiveness of the tumor and a high rate of recurrence. We report one case of a 25-year-old right-handed nurse with no reported pathological history who complained about an ulcero-budding mass of the right little finger evolving one year ago. She would have initially consulted a bonesetter who would have taken care of her by using decoctions. The hand X-ray showed an osteolytic tumor of the first phalanx of the right little finger with a “honeycomb” appearance invading the soft tissues. We carried out the amputation of the radius. The postoperative course was simple with healing of the surgical wound and disappearance of the axillary adenopathy. The surgical specimen after anatomopathology exam concluded to be a grade 2 giant cell tumor of Senerkin.展开更多
Primary malignant giant cell tumor of bone is clinically rare,lack of specificity,and often misdiagnosed.Currently,related literature about this tumor remains scarce.One case of primary malignant giant cell tumor of b...Primary malignant giant cell tumor of bone is clinically rare,lack of specificity,and often misdiagnosed.Currently,related literature about this tumor remains scarce.One case of primary malignant giant cell tumor of bone was diagnosed and treated in our hospital,and the treatment effect was satisfactory.There was no recurrence or metastasis in 2 years of followup.The report is as follows.展开更多
目的评估地诺单抗治疗桡骨远端骨巨细胞瘤(giant cell tumor of bone,GCT)的疗效和安全性,分析地诺单抗对手术方式及预后的影响。方法回顾性分析2014年1月至2016年4月,在围手术期接受地诺单抗治疗的复杂桡骨远端GCT病人7例的临床资料。...目的评估地诺单抗治疗桡骨远端骨巨细胞瘤(giant cell tumor of bone,GCT)的疗效和安全性,分析地诺单抗对手术方式及预后的影响。方法回顾性分析2014年1月至2016年4月,在围手术期接受地诺单抗治疗的复杂桡骨远端GCT病人7例的临床资料。其中,男4例,女3例;年龄为23~33岁,平均28.43岁。所有病人均有明确GCT病理诊断,2例为手术后复发。病人术前接受120 mg地诺单抗皮下注射3~4次,术后根据实际手术类型安排用药。比较病人应用地诺单抗前后手术方案的差异,监测用药过程中的不良反应;随访病人的肿瘤学预后及术后功能恢复。结果病人均按计划用药,用药总次数为4~10次(平均7.71次),用药期间无死亡病例,未见下颌骨坏死,实验室指标未见异常,RECIST评估结果显示:部分缓解5例、疾病稳定2例;6例病人(85.71%)实现外科手术降级(行囊内刮除术5例,瘤段广泛切除2例),术后病理结果提示组织学巨细胞清除率为85.71%(6/7);随访20~41个月,平均26.71个月,7例病人随访期内均未见肿瘤复发;病人术后的肌肉骨骼肿瘤学会(MSTS)93功能评分平均为27.86分(得分率为92.87%),平均臂肩手功能障碍(DASH)评分为7.43分,平均疼痛视觉模拟量表(VAS)评分为1.00分。结论地诺单抗是治疗桡骨远端GCT的有效手段,围手术期用药可降低手术难度,从而实现外科降级并降低复发风险。展开更多
文摘BACKGROUND Aggressive giant cell tumor of the distal fibula is so rare that no consensus on a surgical strategy has been reached.Thus,an appropriate treatment strategy is still important to discuss.CASE SUMMARY A 61-year-old man who had been experiencing progressive swelling of the left lateral malleolus accompanied by pain for half a year was presented at our hospital.He had never been treated prior to coming to our hospital.Preoperative imaging revealed a 10 cm×6 cm mass located in the body of the distal fibula.Pathological biopsies confirmed it was a giant cell tumor.Preoperative examination revealed he had dilated cardiomyopathy with class 3 cardiac function.The cardiologist and anesthesiologist determined that he could tolerate the operation,but the operation should be as short and minimally invasive as possible.With the patient’s consent,we performed a tibiotalar fusion and followed up with him for 2years,finding no recurrence and a satisfactory recovery.CONCLUSION Tibial talus fusion is an effective method for the treatment of distal fibula tumors.
文摘Giant cell tumour of the distal radius is the 3rd most common site after proximal tibia and distal femur. It is locally aggressive and is associated with a high rate of recurrence. Although it is usually treated with various modalities of treatment, wide resection and reconstruction with proximal fibular autograft is most commonly accepted in recurrent cases. The following is a case report of such a case with surgical management.
文摘Giant cell tumor is a benign primary bone tumor. The phalangeal localization is rare. It is distinguished from other locations by the local aggressiveness of the tumor and a high rate of recurrence. We report one case of a 25-year-old right-handed nurse with no reported pathological history who complained about an ulcero-budding mass of the right little finger evolving one year ago. She would have initially consulted a bonesetter who would have taken care of her by using decoctions. The hand X-ray showed an osteolytic tumor of the first phalanx of the right little finger with a “honeycomb” appearance invading the soft tissues. We carried out the amputation of the radius. The postoperative course was simple with healing of the surgical wound and disappearance of the axillary adenopathy. The surgical specimen after anatomopathology exam concluded to be a grade 2 giant cell tumor of Senerkin.
基金on the treatment ofknee osteoarthritis by Kangjian5s three-dimensional model(2020XZ003)。
文摘Primary malignant giant cell tumor of bone is clinically rare,lack of specificity,and often misdiagnosed.Currently,related literature about this tumor remains scarce.One case of primary malignant giant cell tumor of bone was diagnosed and treated in our hospital,and the treatment effect was satisfactory.There was no recurrence or metastasis in 2 years of followup.The report is as follows.
